LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Lista de Ações・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Fechado

SetorSaúde

24.41 -0.89

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

24.2

Máximo

24.62

Indicadores-chave
By Trading Economics
Rendimento	45M 72M
Vendas	14M 279M
P/E Médio do Setor	15.955 108.767
EPS	0.42
Margem de lucro	25.761
Funcionários	653
EBITDA	7.3M 48M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+32.61% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	410M 4.2B
Abertura anterior	25.3
Fecho anterior	24.41

Sentimento de Notícias

By Acuity

34%

66%

79 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

14.845 / N/A Suporte e Resistência

ACADIA Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

1 de mar. de 2026, 23:35 UTC

Notícias Principais

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

1 de mar. de 2026, 23:49 UTC

Conversa de Mercado

Notícias Principais

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

1 de mar. de 2026, 23:47 UTC

Conversa de Mercado

Notícias Principais

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

1 de mar. de 2026, 23:41 UTC

Conversa de Mercado

Notícias Principais

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

1 de mar. de 2026, 23:39 UTC

Conversa de Mercado

Notícias Principais

Global Equities Roundup: Market Talk

1 de mar. de 2026, 23:39 UTC

Conversa de Mercado

Notícias Principais

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

1 de mar. de 2026, 23:36 UTC

Conversa de Mercado

Notícias Principais

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

1 de mar. de 2026, 23:24 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

1 de mar. de 2026, 23:24 UTC

Conversa de Mercado

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

1 de mar. de 2026, 23:21 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 de mar. de 2026, 23:21 UTC

Conversa de Mercado

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

1 de mar. de 2026, 23:19 UTC

Notícias Principais

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

1 de mar. de 2026, 23:17 UTC

Notícias Principais

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

1 de mar. de 2026, 23:14 UTC

Notícias Principais

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

1 de mar. de 2026, 22:55 UTC

Notícias Principais

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

1 de mar. de 2026, 22:54 UTC

Notícias Principais

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

1 de mar. de 2026, 22:53 UTC

Notícias Principais

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

1 de mar. de 2026, 22:38 UTC

Conversa de Mercado

Notícias Principais

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

1 de mar. de 2026, 22:21 UTC

Ganhos

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

1 de mar. de 2026, 22:17 UTC

Conversa de Mercado

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

1 de mar. de 2026, 22:13 UTC

Conversa de Mercado

Notícias Principais

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

1 de mar. de 2026, 22:00 UTC

Conversa de Mercado

Notícias Principais

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

1 de mar. de 2026, 21:40 UTC

Conversa de Mercado

Notícias Principais

Spot Gold Up as Investors Shield Against Risk -- Market Talk

1 de mar. de 2026, 21:35 UTC

Conversa de Mercado

Notícias Principais

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

1 de mar. de 2026, 21:30 UTC

Conversa de Mercado

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

1 de mar. de 2026, 21:27 UTC

Conversa de Mercado

Notícias Principais

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

1 de mar. de 2026, 21:19 UTC

Conversa de Mercado

Notícias Principais

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

1 de mar. de 2026, 20:58 UTC

Conversa de Mercado

Notícias Principais

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

1 de mar. de 2026, 20:40 UTC

Conversa de Mercado

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

1 de mar. de 2026, 20:24 UTC

Conversa de Mercado

Notícias Principais

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Comparação entre Pares

Variação de preço

ACADIA Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

32.61% parte superior

Previsão para 12 meses

Média 32.57 USD 32.61%

Máximo 40 USD

Mínimo 23 USD

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para ACADIA Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

15 ratings

Comprar

Manter

Vender

Com base em 15 analistas que deram avaliações de ações para ACADIA Pharmaceuticals Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

14.845 / N/ASuporte e Resistência

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentimento

By Acuity

79 / 352 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.